Interdisciplinary Epidemiologic Consortium to Investigate T-cell Response in Colorectal Cancer
Interdisciplinary Epidemiologic Consortium to Investigate T-cell Response in Colorectal Cancer
批准号:
10471775
负责人:
Shuji Ogino
金额:
$65.6万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-05-01 至 2026-04-30
关键词:
AccountingAdaptive Immune SystemAddressAlcohol consumptionAreaAspirinBacterial GenesBacterial ToxinsBacteroides fragilis toxinCD3 AntigensCD8B1 geneCancer PrognosisCellsCharacteristicsColorectal CancerColorectal NeoplasmsDNA sequencingDataDevelopmentEpidemiologyEvolutionFOXP3 geneFusobacterium nucleatumGenesGeneticGenetic VariationGenotypeHLA AntigensHumanImmuneImmune responseImmune systemImmunofluorescence ImmunologicImmunoglobulinsImmunohistochemistryImmunotherapeutic agentKiller CellsLife StyleMachine LearningMemoryMutateObesityObservational StudyOncogenicPathogenicityPatient-Focused OutcomesPatternPhenotypePhysical activityPreventionPrognostic FactorProteinsRas/RafReceptor GeneResearchResourcesRoleSignal PathwaySignaling ProteinSmokingSomatic MutationSpatial DistributionT cell responseT memory cellT-LymphocyteT-Lymphocyte SubsetsT-cell receptor repertoireTumor AntigensTumor TissueUncertaintyVariantWNT Signaling PathwayWorkadaptive immune responsebiomarker panelcancer survivalcell mediated immune responsecell typecolon cancer family registrycolon cancer patientscolorectal cancer treatmentcombinatorialdensitydigital imagingepidemiologic dataepidemiology studyfollow-upgenetic epidemiologygenetic resourcegenetic variantgenome-widehomeobox protein PITX1immune functioninsightlifestyle factorsmacrophagemicrobialneoantigensneoplastic cellnovelprognosticprognostic significanceprospectiveresponsestemsurvival outcometumortumor microenvironment
中文摘要
项目摘要/摘要
免疫系统在许多肿瘤类型的进化和进展中具有关键影响,包括
结直肠癌(CRC)特别是,在CRC中存在强烈的T细胞反应,表明
适应性免疫系统一直与更好的患者预后相关。因此,最近开发的
免疫治疗方法通常试图利用适应性免疫反应。免疫细胞是一种
肿瘤微环境的组成部分,并与肿瘤细胞动态相互作用。然而,
我们对T细胞反应的复杂性和驱动这种反应的因素的理解仍然存在
有限的。这项建议的目的是确定与T细胞相关的遗传、生活方式和肿瘤因素
结直肠癌中的细胞反应,并表征这种反应的生存意义。具体地说,在目标1中我们
我将研究个人特征与结直肠癌患者T细胞反应的关系,包括(1a)的作用
人类白细胞抗原和杀伤细胞免疫球蛋白样受体的种系遗传变异
(B)生活方式因素(例如,使用阿司匹林、吸烟、饮酒)。在《目标2》中,我们将专注于
关于与T细胞反应有关的几个结直肠肿瘤特征,包括(2a)存在
核梭杆菌和细菌毒素基因在结直肠癌中的表达,以及(2b)关键信号转导中的体细胞突变
途径(例如,WNT信号和RAS/RAF)。在目标3中,我们将评估不同方面的关联
T细胞应答与CRC存活率的关系,说明了已知的预后因素和在
目标1-2。为了实现这些目标,我们建议评估特定T细胞的密度和空间分布
使用多重免疫荧光(MIF)来量化表达水平和共表达模式的亚群
CD3、CD4、CD8、CD45RO、FOXP3在单细胞水平的表达。这种多元化的评估将使我们能够
检查多种T细胞反应指标在结直肠癌中的流行病学和预后相关性。这
研究将利用结直肠癌联合会的遗传学和流行病学资源
(GECCO)和结肠癌家庭登记(CCFR)。GECCO-CCFR是一项大型协作工作
在对儿童权利公约的观察性研究之间。我们已经完成了全基因组生殖系的基因分型
关于各种生活方式因素和所有人的个人特征的统一流行病学数据
参与性研究。我们正在对205个人类基因和一个小的
结直肠癌组织中细菌基因的数量。生存的前瞻性随访正在进行中,我们已经
协调现有的生存数据。通过这个项目,我们将在CRC中添加关于T细胞应答的信息
>;将2,500个CRC案例发送到GECCO-CCFR资源。这个项目提供了一个前所未有的机会
结直肠癌患者T细胞反应的流行病学调查及其与个体的关系
和肿瘤的特征。通过这项新颖的研究获得的见解最终可能会为这一发展提供信息
以及有针对性地实施新的免疫治疗和免疫预防战略。
英文摘要
PROJECT SUMMARY / ABSTRACT
The immune system has pivotal influence in the evolution and progression of many tumor types, including
colorectal cancer (CRC). In particular, the presence of a strong T cell response in CRC, indicating activation of
the adaptive immune system, has been associated with better patient outcomes. As such, recently developed
immunotherapeutic approaches often attempt to harness the adaptive immune response. Immune cells are an
integral component of the tumor microenvironment, and dynamically interact with neoplastic cells. However,
our understanding as to the complexity of the T cell response and the factors that drive this response remains
limited. The objective of this proposal is to identify genetic, lifestyle, and tumor factors associated with the T
cell response in CRC, and to characterize the survival implications of that response. Specifically, in Aim 1 we
will examine the relationship of personal characteristics with T cell response in CRC, including the role of (1a)
germline genetic variation within human leukocyte antigen (HLA) and killer-cell immunoglobulin-like receptor
(KIR) genes, and (1b) lifestyle factors (e.g., aspirin use, smoking, alcohol consumption). In Aim 2 we will focus
on several colorectal tumor characteristics as they relate to T cell response, including (2a) the presence of
Fusobacterium nucleatum and bacterial toxin genes in CRC, and (2b) somatic mutations in key signaling
pathways (e.g., WNT signaling and RAS/RAF). In Aim 3, we will evaluate the associations of different aspects
of T cell response with CRC survival, accounting for known prognostic factors and the relationships identified in
Aims 1-2. To achieve these Aims, we propose to assess the density and spatial distribution of specific T cell
subsets using multiplexed immunofluorescence (mIF) to quantify expression levels and co-expression patterns
of CD3, CD4, CD8, CD45RO, and FOXP3 at the single cell level. This multiplexed assessment will allow us to
examine the epidemiologic and prognostic relevance of numerous metrics of T cell response in CRC. This
research will leverage the resources of the Genetics and Epidemiology of Colorectal Cancer Consortium
(GECCO) and the Colon Cancer Family Registry (CCFR). GECCO-CCFR is a large collaborative effort
between observational studies of CRC. We have completed genome-wide germline genotyping and have
harmonized epidemiologic data regarding a variety of lifestyle factors and personal characteristics for all
participating studies. We are conducting DNA sequencing with a panel of 205 human genes and a small
number of bacterial genes in CRC tumor tissue. Prospective follow-up for survival is ongoing, and we have
harmonized existing survival data. Through this project, we will add information on T cell response in CRC for
>2,500 CRC cases to the GECCO-CCFR resource. This project provides an unprecedented opportunity to
investigate the epidemiology of the T cell response in CRC and the relationship of that response with personal
and tumor characteristics. Insights gained through this novel study could ultimately inform the development
and targeted implementation of emerging immunotherapeutic and immunopreventative strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Interdisciplinary Epidemiologic Consortium to Investigate T-cell Response in Colorectal Cancer
-
批准号:10686351
-
项目类别:
-
资助金额:$69.2万
-
财政年份:2020
-
负责人:Shuji Ogino
-
依托单位:
Interdisciplinary Epidemiologic Consortium to Investigate T-cell Response in Colorectal Cancer
-
批准号:10601279
-
项目类别:
-
资助金额:$14.74万
-
财政年份:2020
-
负责人:Shuji Ogino
-
依托单位:
Accelerating Transdisciplinary Epidemiology of Colorectal Cancer
-
批准号:10020904
-
项目类别:
-
资助金额:$75.54万
-
财政年份:2019
-
负责人:Shuji Ogino
-
依托单位:
Accelerating Transdisciplinary Epidemiology of Colorectal Cancer
-
批准号:10247006
-
项目类别:
-
资助金额:$93.11万
-
财政年份:2019
-
负责人:Shuji Ogino
-
依托单位:
Accelerating Transdisciplinary Epidemiology of Colorectal Cancer
-
批准号:9123565
-
项目类别:
-
资助金额:$87.22万
-
财政年份:2015
-
负责人:Shuji Ogino
-
依托单位:
Accelerating Transdisciplinary Epidemiology of Colorectal Cancer
-
批准号:9318464
-
项目类别:
-
资助金额:$87.0万
-
财政年份:2015
-
负责人:Shuji Ogino
-
依托单位:
Accelerating Transdisciplinary Epidemiology of Colorectal Cancer
-
批准号:8955856
-
项目类别:
-
资助金额:$87.35万
-
财政年份:2015
-
负责人:Shuji Ogino
-
依托单位:
Epigenetic Events and Colorectal Cancer Epidemiology
-
批准号:8466939
-
项目类别:
-
资助金额:$51.05万
-
财政年份:2010
-
负责人:Shuji Ogino
-
依托单位:
Epigenetic Events and Colorectal Cancer Epidemiology
-
批准号:8676715
-
项目类别:
-
资助金额:$45.98万
-
财政年份:2010
-
负责人:Shuji Ogino
-
依托单位:
Epigenetic Events and Colorectal Cancer Epidemiology
-
批准号:8101809
-
项目类别:
-
资助金额:$56.39万
-
财政年份:2010
-
负责人:Shuji Ogino
-
依托单位:
Epigenetic Events and Colorectal Cancer Epidemiology
-
批准号:8259534
-
项目类别:
-
资助金额:$50.26万
-
财政年份:2010
-
负责人:Shuji Ogino
-
依托单位:
Molecular Epidemiology of Colorectal Cancer
-
批准号:7922918
-
项目类别:
-
资助金额:$10.8万
-
财政年份:2009
-
负责人:Shuji Ogino
-
依托单位:
Molecular Epidemiology of Colorectal Cancer
-
批准号:7662532
-
项目类别:
-
资助金额:$13.88万
-
财政年份:2007
-
负责人:Shuji Ogino
-
依托单位:
Molecular Epidemiology of Colorectal Cancer
-
批准号:7860487
-
项目类别:
-
资助金额:$10.98万
-
财政年份:2007
-
负责人:Shuji Ogino
-
依托单位:
Molecular Epidemiology of Colorectal Cancer
-
批准号:7261457
-
项目类别:
-
资助金额:$13.88万
-
财政年份:2007
-
负责人:Shuji Ogino
-
依托单位:
Molecular Epidemiology of Colorectal Cancer
-
批准号:7479192
-
项目类别:
-
资助金额:$13.88万
-
财政年份:2007
-
负责人:Shuji Ogino
-
依托单位:
海外基金